Marine Compounds and Cancer: Updates 2020

Dyshlovoy, Sergey A.; Honecker, Friedemann

doi:10.3390/md18120643

Cited by 32 publications

(31 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Brentuximab vedotin (SGN-35, Table S1 and Figure 8 ) is an ADC comprising an anti-CD30 antibody conjugated by a protease-cleavable linker to the potent anti-microtubule agent, MMAE [ 149 , 151 ]. It gained the United States Food and Drug Administration (FDA) approval in 2011 for the treatment of Hodgkin lymphoma and systemic anapla sms known to stic large cell lymphoma [ 36 ].…”

Section: Marine-derived Small Peptides In Clinical Trialsmentioning

confidence: 99%

“…Compared with high-molecular-weight peptides, low-molecular-weight peptides show greater molecular mobility and diffusivity, contributing to their enhanced interaction with cancer cell components and increasing their anticancer activity [ 34 ]. Nowadays, several newly discovered anticancer small peptides and their derivatives thereof from marine organisms have been widely applied to clinical research [ 35 , 36 , 37 ] ( Figure 1 ). Marine small peptides are molecules that participates in all processes of life activities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Small Peptides of Marine Origin in Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the leading causes of death in the world, and antineoplastic drug research continues to be a major field in medicine development. The marine milieu has thousands of biological species that are a valuable source of novel functional proteins and peptides, which have been used in the treatment of many diseases, including cancer. In contrast with proteins and polypeptides, small peptides (with a molecular weight of less than 1000 Da) have overwhelming advantages, such as preferential and fast absorption, which can decrease the burden on human gastrointestinal function. Besides, these peptides are only connected by a few peptide bonds, and their small molecular weight makes it easy to modify and synthesize them. Specifically, small peptides can deliver nutrients and drugs to cells and tissues in the body. These characteristics make them stand out in relation to targeted drug therapy. Nowadays, the anticancer mechanisms of the small marine peptides are still largely not well understood; however, several marine peptides have been applied in preclinical treatment. This paper highlights the anticancer linear and cyclic small peptides in marine resources and presents a review of peptides and the derivatives and their mechanisms.

show abstract

Section: Marine-derived Small Peptides In Clinical Trialsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Recent Advances in Small Peptides of Marine Origin in Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cycloartane derivatives, cimyunnin A ( 44) with an unusual fused cyclopentenone ring G, together with cimyunnin D (45), possessing a highly rearranged c-lactone ring F, were found in the fruit of Cimicifuga yunnanensis and their structures were determined using physical-chemical methods [85]. 3,4-Seco-cycloartane triterpenoid which had rearranged 5/6 consecutive carbocycle rings C/D, named ananosins A (46), was isolated from the stems of Kadsura ananosma [86].…”

Section: Cyclopropane Containing Steroids and Triterpenoidsmentioning

confidence: 99%

Antitumor Profile of Carbon-Bridged Steroids (CBS) and Triterpenoids

2021

View full text Add to dashboard Cite

This review focuses on the rare group of carbon-bridged steroids (CBS) and triterpenoids found in various natural sources such as green, yellow-green, and red algae, marine sponges, soft corals, ascidians, starfish, and other marine invertebrates. In addition, this group of rare lipids is found in amoebas, fungi, fungal endophytes, and plants. For convenience, the presented CBS and triterpenoids are divided into four groups, which include: (a) CBS and triterpenoids containing a cyclopropane group; (b) CBS and triterpenoids with cyclopropane ring in the side chain; (c) CBS and triterpenoids containing a cyclobutane group; (d) CBS and triterpenoids containing cyclopentane, cyclohexane or cycloheptane moieties. For the comparative characterization of the antitumor profile, we have added several semi- and synthetic CBS and triterpenoids, with various additional rings, to identify possible promising sources for pharmacologists and the pharmaceutical industry. About 300 CBS and triterpenoids are presented in this review, which demonstrate a wide range of biological activities, but the most pronounced antitumor profile. The review summarizes biological activities both determined experimentally and estimated using the well-known PASS software. According to the data obtained, two-thirds of CBS and triterpenoids show moderate activity levels with a confidence level of 70 to 90%; however, one third of these lipids demonstrate strong antitumor activity with a confidence level exceeding 90%. Several CBS and triterpenoids, from different lipid groups, demonstrate selective action on different types of tumor cells such as renal cancer, sarcoma, pancreatic cancer, prostate cancer, lymphocytic leukemia, myeloid leukemia, liver cancer, and genitourinary cancer with varying degrees of confidence. In addition, the review presents graphical images of the antitumor profile of both individual CBS and triterpenoids groups and individual compounds.

show abstract

“…Between 2018 and the end of 2020, five new marine-derived drugs have been approved (plitidepsin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, and lurbinectedin) in addition to the four anticancer drugs already approved before 2018 (cytarabine, trabectedin, eribulin mesylate, and the antibody–drug conjugate (ADC) brentuximab vedotin). Hence, nine marine-derived drugs are currently available as anticancer chemotherapeutics ( Figure 1 ) [ 4 ]. In addition, a great number of marine-derived compounds are actually in preclinical investigations, while 19 are being tested in different stages of clinical trials [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, a great sylate, and the antibody-drug conjugate (ADC) brentuximab vedotin). Hence, nine marine-derived drugs are currently available as anticancer chemotherapeutics (Figure 1) [4]. In addition, a great number of marine-derived compounds are actually in preclinical investigations, while 19 are being tested in different stages of clinical trials [4].…”

Section: Introductionmentioning

confidence: 99%

Marine Anthraquinones: Pharmacological and Toxicological Issues

et al. 2021

View full text Add to dashboard Cite

The marine ecosystem, populated by a myriad of animals, plants, and microorganisms, is an inexhaustible reservoir of pharmacologically active molecules. Among the multiple secondary metabolites produced by marine sources, there are anthraquinones and their derivatives. Besides being mainly known to be produced by terrestrial species, even marine organisms and the uncountable kingdom of marine microorganisms biosynthesize anthraquinones. Anthraquinones possess many different biological activities, including a remarkable antitumor activity. However, due to their peculiar chemical structures, anthraquinones are often associated with toxicological issues, even relevant, such as genotoxicity and mutagenicity. The aim of this review is to critically describe the anticancer potential of anthraquinones derived from marine sources and their genotoxic and mutagenic potential. Marine-derived anthraquinones show a promising anticancer potential, although clinical studies are missing. Additionally, an in-depth investigation of their toxicological profile is needed before advocating anthraquinones as a therapeutic armamentarium in the oncological area.

show abstract

Marine Compounds and Cancer: Updates 2020

Abstract: By the end of the year 2020, there are nine marine-derived anticancer drugs available on the market, and the field is currently growing exponentially [...]

Cited by 32 publications

References 41 publications

Recent Advances in Small Peptides of Marine Origin in Cancer Therapy

Recent Advances in Small Peptides of Marine Origin in Cancer Therapy

Antitumor Profile of Carbon-Bridged Steroids (CBS) and Triterpenoids

Marine Anthraquinones: Pharmacological and Toxicological Issues

Contact Info

Product

Resources

About